Supernus Pharmaceuticals, Inc. SUPN R2KR3KPHARMA
Company Overview
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Why Investors Should Care
Revenue has grown at a 80.1% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $718.95M (+8.6% YoY); net profit $-38.55M.
- Trailing 12 Months Year-on-year growth — revenue +32.4%, earnings -152.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 80.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 80.06% |
| 1 Year: | 32.40% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -152.19% |
Stock Price Performance
| 1 Year: | +2.09% |
| 6 Months: | -19.19% |
| 3 Months: | -2.73% |
| 1 Month: | -6.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.99 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 80.1% over 5 years.
- Generates positive free cash flow.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SUPN Supernus Pharmaceuticals, Inc. R2KR3KPHARMA | 43.53 | -22.67 | $2.53B | 0.00% | -5.59% | -10.49% | 80.06% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 104.69M | 102.14M | - | 94.98M | 126.73M | 155.13M | 130.93M | 141.33M | 148.46M | 152.51M | 170.05M | 177.35M | 153.76M | 135.56M | 153.88M | 143.64M | 168.32M | 175.69M | 149.82M | 165.45M | 192.10M | 207.71M | 219.06M |
| Operating Income | 3.43M | 3.08M | 5.08M | - | 6.44M | 11.64M | 19.84M | 16.30M | 16.79M | 26.07M | 22.34M | 34.34M | 31.39M | 35.72M | 37.48M | 39.85M | 25.43M | 42.60M | 39.73M | 40.82M | 29.01M | 45.55M | 56.14M | 13.21M | 34.11M | 32.60M | 1.97M | 11.35M | -1.52M | 5.18M | -17.59M | 8.14M | -3.15M | 22.57M | 40.84M | -10.26M | 12.14M | -60.23M | -8.33M | -57.96M |
| Net Income | 738.00K | 2.44M | 3.92M | 6.85M | 4.83M | 10.25M | 61.83M | 14.32M | 10.30M | 17.37M | 15.96M | 13.66M | 26.35M | 30.74M | 28.01M | 25.89M | 18.34M | 32.73M | 28.86M | 33.13M | 21.52M | 34.67M | 40.00M | 5.69M | 23.73M | 21.56M | 25.62M | 7.87M | 1.75M | 16.95M | -831.00K | -15.98M | 124.00K | 19.92M | 38.50M | -11.83M | 22.50M | -45.12M | -2.29M | -58.37M |
| Diluted EPS | 0.02 | 0.04 | 0.08 | 0.14 | 0.08 | 0.18 | 1.18 | 0.26 | 0.19 | 0.32 | 0.29 | 0.26 | 0.49 | 0.57 | 0.52 | 0.48 | 0.34 | 0.61 | 0.54 | 0.62 | 0.40 | 0.65 | 0.74 | 0.11 | 0.43 | 0.40 | 0.43 | 0.14 | 0.03 | 0.29 | -0.02 | -0.29 | 0.00 | 0.36 | 0.69 | -0.21 | 0.40 | -0.80 | -0.04 | -1.01 |
| R&D Expense | 3.68M | 6.88M | 9.13M | - | 10.56M | 11.11M | 7.87M | - | 9.60M | 10.82M | 12.98M | - | 18.91M | 20.04M | 20.42M | - | 15.39M | 16.97M | 16.94M | - | 18.94M | 22.25M | 16.84M | 34.28M | 15.46M | 19.65M | 20.84M | 16.39M | 19.55M | 21.21M | 24.38M | 22.66M | 24.93M | 26.18M | 29.04M | 26.93M | 22.11M | 29.37M | 39.44M | 29.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.00K | 803.00K | 1.48M | 12.02M | 92.68M | 147.47M | 215.00M | 302.24M | 408.90M | 392.75M | 520.40M | 579.77M | 667.24M | 607.52M | 661.82M | 718.95M |
| Operating Income | -40.12M | -37.75M | -42.17M | -61.92M | -5.28M | 20.84M | 54.22M | 99.54M | 144.44M | 148.57M | 173.70M | 86.03M | 46.12M | -5.27M | 81.67M | -62.28M |
| Net Income | -38.46M | 53.81M | -46.28M | -92.27M | -10.93M | 13.94M | 91.22M | 57.28M | 110.99M | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M | 73.86M | -38.55M |
| Diluted EPS | - | - | -2.72 | -2.90 | -0.26 | 0.28 | 1.76 | 1.08 | 2.05 | 2.10 | 2.36 | 0.98 | 1.04 | 0.02 | 1.32 | -0.68 |
| R&D Expense | 35.15M | 30.63M | 23.52M | 17.25M | 19.59M | 29.14M | 42.79M | 49.58M | 89.21M | 69.10M | 75.96M | 90.47M | 74.55M | 91.59M | 108.80M | 106.23M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 53.73M | 93.99M | 111.00M | 137.51M | 188.63M | 309.57M | 424.46M | 977.81M | 1.16B | 1.50B | 1.69B | 1.70B | 1.28B | 1.37B | 1.45B |
| Total Equity | -6.16M | -44.32M | 9.44M | 57.57M | 33.46M | 40.70M | 88.01M | 191.75M | 267.48M | 453.02M | 595.43M | 744.86M | 815.85M | 886.20M | 921.52M | 1.04B | 1.06B |
| Cash & Equivalents | 31.41M | 23.74M | 48.54M | 40.30M | 32.98M | 36.40M | 33.50M | 66.40M | 100.30M | 192.25M | 181.38M | 288.64M | 203.43M | 93.12M | 75.05M | 69.33M | 128.45M |
| Long Term Debt | - | - | - | 23.23M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 44.29M | 36.42M | 77.53M | 66.15M | 100.62M | 117.81M | 156.98M | 524.79M | 564.85M | 759.24M | 873.30M | 816.30M | 356.16M | 332.34M | 390.93M |
| Current Liabilities | - | - | 18.77M | 22.98M | 26.40M | 27.49M | 56.93M | 80.74M | 123.00M | 161.35M | 160.59M | 245.11M | 315.38M | 687.96M | 290.20M | 292.40M | 338.17M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -32.54M | -36.19M | -47.20M | -57.95M | 7.73M | 34.52M | 66.81M | 114.64M | 128.99M | 143.13M | 138.40M | 127.13M | 116.83M | 111.08M | 171.95M | 47.33M |
| Investing Cash Flow | 25.82M | 33.90M | -48.96M | -12.11M | -4.89M | -39.29M | -35.96M | -86.42M | -413.48M | -157.92M | -34.70M | -81.91M | -216.66M | 268.73M | -189.87M | 4.11M |
| Financing Cash Flow | -944.00K | 27.09M | 87.92M | 62.74M | 570.00K | 1.87M | 2.05M | 5.68M | 376.44M | 3.93M | 3.56M | -130.42M | -10.48M | -397.88M | 12.19M | 9.13M |
| Capital Expenditure | -294.00K | -685.00K | -753.00K | -1.65M | -593.00K | -2.10M | -1.60M | -2.03M | -844.00K | -2.74M | -3.45M | - | -412.00K | -551.00K | -725.00K | -1.34M |
| Free Cash Flow | -32.84M | -36.87M | -47.95M | -59.59M | 7.14M | 32.42M | 65.21M | 112.61M | 128.14M | 140.39M | 134.95M | - | 116.41M | 110.53M | 171.23M | 45.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -37,851.9% | -4,701.4% | -2,849.3% | -515.2% | -5.7% | 14.1% | 25.2% | 32.9% | 35.3% | 37.8% | 33.4% | 14.8% | 6.9% | -0.9% | 12.3% | -8.7% |
| Net Margin % | -36,285.8% | 6,701.7% | -3,127.3% | -767.7% | -11.8% | 9.5% | 42.4% | 19.0% | 27.1% | 28.8% | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% |
| ROE % | 86.8% | 569.9% | -80.4% | -275.7% | -26.8% | 15.8% | 47.6% | 21.4% | 24.5% | 19.0% | 17.0% | 6.5% | 6.9% | 0.1% | 7.1% | -3.6% |
| ROCE % | - | -108.0% | -59.4% | -73.2% | -4.8% | 15.8% | 23.7% | 33.0% | 17.7% | 14.9% | 13.8% | 6.3% | 4.5% | -0.5% | 7.6% | -5.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.09% | 9.35M | $408.88M |
| 2 | Millennium Management Llc | 6.63% | 3.85M | $168.50M |
| 3 | Vanguard Portfolio Management LLC | 5.69% | 3.31M | $144.55M |
| 4 | Armistice Capital, LLC | 4.55% | 2.65M | $115.72M |
| 5 | Vanguard Capital Management LLC | 4.33% | 2.52M | $110.06M |
| 6 | State Street Corporation | 4.23% | 2.46M | $107.57M |
| 7 | Nomura Asset Management International Inc | 4.09% | 2.38M | $104.00M |
| 8 | Dimensional Fund Advisors LP | 3.58% | 2.08M | $90.87M |
| 9 | Geode Capital Management, LLC | 2.70% | 1.57M | $68.66M |
| 10 | Stephens Investment Management Group LLC | 2.56% | 1.49M | $64.97M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SUPN
Supernus Pharmaceuticals (SUPN) Stock May Be A Bargain After Merger News - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOQVFRcE5MckVuNXo4algxa1E4LXVBenRHcGpvS1lqNEEzd29XbTNRRXN3Q19famRiRmo3RmtlckpyQ0VXQnBaS2FLUGZ6LVNBaUxxOEFudG9XeDN0NGJsMnZ5OHFienowdzQxcE1HejJwUlNTR0JYRmpWTnA1NG1sUFByNTYweDNzZTlRVU…
Supernus Pharmaceuticals (SUPN) Stock Looks Reasonable On Sales While Returns Look Strong - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOOTdtOHRSd2pEc1ZEcTM2b05ZN282aS1DLWZ3ZHNFSDdkbTZzQUlsSy1Fb290TVVwUEI3SWpJMDJtRFE2ekhhWmNSVV9HY1hoaFhHTWEyYjdIMGFSQkRJZzFjU0puNHl3bE9OdkVpZ1JDc1FYbzVFNURsOXR0NEJDbnprLThYUFl6ZUxhbj…
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Super - The National Law Review
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPY1Z1OFJyUG9rVkRsZTJ5SlFaUzhFS0VsOXplMVFCYlhJQUdDSU1JeEQtM25CZGxrOHdLaDRxcEU5ZFREYVpBeEx6cndDM014MFlILXBzQmtOS084UUtieWRjempCYUctZHllSkV2dHZWQWZNakZPVVk2ci1KS3pWbEdsNThsUUtjay1ma0…
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today - StockStory
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOQzFmMFNfbUpIbnBmSGRoY3RKYlBFY3FnaXZVNVVncjhNU1dsbFpZMGNuTmFQSTdwa3BBT1RwUDdQbzRXNEVPSks2TDBMZERpRnZKNUNETjVlMk5uaWxnSEU3RmR1T2JKNEpXSmZQNVZNM3U1UG9HX2p1STJmY1VSWEZfY3lseFdHMFZKX0…
Trading the Move, Not the Narrative: (SUPN) Edition - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxQLXJ2LXl4NHRiSm1uaTYyTk5NZVg5MnBYWGhkQk5GM3JHeGREd2Q1bnFnTndkYmVIU3pVZlBYemczYkZ3RXRtQlhwMVVZX2F6U08xNnZNcjI1c1JqZ2JGdkV0TTdpYVc1djZrYVV1SUk3QUIwQm9hQ3ZDT2staEJRRlhQQkJ5WGpiUm1KdT…
Supernus Pharmaceuticals (SUPN) CEO exercises PSUs, withholds shares for taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQMUdUalkyM0xqZzVIdGxqcTFnYnZ3TWwtZ09IaDNLckF1SVFlSnQ0OTF3bWN3MVh0d2ozQWxncWthYmVRV2h4bnp5YWVWSk1EUGkyUjRkZ1NCdXhtdHVTRWVqOGwwTk9jcndpTEg3eW1uWWRQLU82Mkphd3N4cjhKMDBKTXAtSUYzWUNpQU…
SUPN — Frequently Asked Questions
What is the current share price of Supernus Pharmaceuticals, Inc. (SUPN)?
As of 2026-09-07 16:24 PDT, Supernus Pharmaceuticals, Inc. (SUPN) trades at $43.53 on NasdaqGM. Its 52-week range is $42.00 to $57.00.
What is the market capitalisation of SUPN?
Supernus Pharmaceuticals, Inc. (SUPN) has a market capitalisation of $2.53B on NasdaqGM.
What is the P/E ratio of SUPN?
SUPN trades at a trailing price-to-earnings (P/E) ratio of -22.67. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.69.
What is the return on equity (ROE) of SUPN?
SUPN has a return on equity (ROE) of -10.49%. Its return on capital employed (ROCE) is -5.59%.
Is SUPN a good stock to buy?
This page provides a data-driven analysis of Supernus Pharmaceuticals, Inc. (SUPN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.